Phase I, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK's Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Japanese Subjects Aged 60-80 Years
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007833/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2
doses of GSK Biologicals' RSV candidate vaccine adjuvanted with AS01B for the prevention of
lower respiratory tract diseases caused by RSV in ethnic Japanese adults 60-80 years of age.
提供机构：
Vivli
创建时间：
2022-04-25
